Positive Topline Phase III Results Show Roche’s Vabysmo Improved vision for People Living With Retinal Vein Occlusion (RVO)
Vabysmo achieved its primary endpoint of non-inferiority to aflibercept in RVO in the BALATON and COMINO clinical trials Vabysmo was generally well tolerated, with a safety profile consistent with previous trials Vabysmo is the first… Read More




